Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Inedita Bio Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is under the review of 1 distinct examiner, SHARMA, SANTOSH. The portfolio is currently active in 1 distinct art unit, which provides a specific technical context for this biopharmaceutical filing. This focused activity ensures that the biotechnology claims are evaluated within the designated technical division. Practitioners should focus their strategy on the requirements of the assigned examiner and the standards of the 1 distinct art unit. The current data reflects a precise effort to secure intellectual property for a specific innovation.
SHARMA, SANTOSH is the busiest examiner. As there is only the 1 pending office action in total, this official manages the company's entire active prosecution effort. This concentrated workload means that the success of the company's current patent strategy is dependent on the interactions with this official. The presence of the action within the Biotechnology & Pharmaceuticals area suggests a rigorous examination process. Practitioners must ensure that their technical arguments are robust and specifically tailored to the nuances of the 1 distinct art unit involved. This arrangement allows for a direct communication channel between the applicant and the patent office to resolve the 1 pending office action. The 1 distinct examiner provides a singular point of review for the company's biotechnology claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHARMA, SANTOSH | 1 | 73.3% | +29.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844880 | METHODS AND COMPOSITIONS FOR INTRON MEDIATED- EXPRESSION OF REGULATORY ELEMENTS FOR TRAIT DEVELOPMENT | SHARMA, SANTOSH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844880 | METHODS AND COMPOSITIONS FOR INTRON MEDIATED- EXPRESSION OF REGULATORY ELEMENTS FOR TRAIT DEVELOPMENT | SHARMA, SANTOSH | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844880 | METHODS AND COMPOSITIONS FOR INTRON MEDIATED- EXPRESSION OF REGULATORY ELEMENTS FOR TRAIT DEVELOPMENT | SHARMA, SANTOSH | 1663 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInedita Bio Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Santosh Sharma has the most, with 1 of Inedita Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.